Table 1 Selected baseline demographic and clinical characteristics of 24 patients with metastatic MITF family translocation renal cell carcinoma treated with an immune checkpoint inhibitor
Characteristics | Number of patients | Percentage of patients |
|---|---|---|
Sex | ||
Male | 4 | 20 |
Female | 20 | 80 |
Age, years | ||
Median | 34 | |
Range | 3–79 | |
≤ 34 | 11 | 46 |
> 34 | 13 | 54 |
Karnofsky score | ||
≤ 80 | 9 | 40 |
> 80 | 13 | 60 |
Translocation type | ||
TFE3 | 21 | 88 |
TFEB | 3 | 12 |
Common site of metastasis | ||
Lymph nodes | 15 | 63 |
Lung | 8 | 33 |
Liver | 8 | 33 |
Bone | 8 | 33 |
Heng score | ||
0 (favorable) | 2 | 8 |
1–2 (intermediate) | 18 | 75 |
3–4- 5 (poor) | 4 | 17 |
First-line therapy | ||
Sunitinib | 15 | 63 |
Pazopanib | 4 | 17 |
Sorafenib | 1 | 4 |
m-TOR inhibitor | 2 | 8 |
High dose IL2 | 1 | 4 |